The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening

Sanket S Dhruva^{1

2}, Rebecca Smith-Bindman^{2

3}, Rita F Redberg^{2

4}

Affiliations

¹ Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California.
² Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco, School of Medicine.
⁴ Division of Cardiology, Department of Medicine, University of California, San Francisco, School of Medicine.

Editorial

Sanket S Dhruva et al. JAMA Intern Med. 2023.

. 2023 Oct 1;183(10):1051-1053.

doi: 10.1001/jamainternmed.2023.3610.

Sanket S Dhruva^{1

2}, Rebecca Smith-Bindman^{2

3}, Rita F Redberg^{2

4}

¹ Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California.
² Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
³ Department of Epidemiology and Biostatistics, University of California, San Francisco, School of Medicine.
⁴ Division of Cardiology, Department of Medicine, University of California, San Francisco, School of Medicine.

No abstract available

Comment on

Assessing the Clinical Utility of Liquid Biopsies Across 5 Potential Indications From Therapy Selection to Population Screening: A Review.
Carr DJ, Welch HG. Carr DJ, et al. JAMA Intern Med. 2023 Oct 1;183(10):1144-1151. doi: 10.1001/jamainternmed.2023.3603. JAMA Intern Med. 2023. PMID: 37639262